Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs S&P Global Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while S&P Global Inc trades at $439.77 (market cap $129.91B). The key difference: S&P Global Inc is far larger — about 16.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and S&P Global Inc pays a 0.88% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SPGI | |
|---|---|---|
Market Cap | $8.04B | $129.91B |
Sector | Health | Financials |
52-Week High | $339.75 | $534.79 |
52-Week Low | $241.71 | $370.42 |
Enterprise Value | $7.85B | $141.87B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
S&P Global (SPGI) trades at $437.84, up 1.7% today, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $15.34B and net income margin of 30.36%. Recent developments include the completion of the Mobility Global spinoff and a strategic shift toward AI-driven market intelligence solutions, positioning the company for sustained growth amid favorable debt issuance trends.
The outlook for SPGI is positive, driven by margin expansion targets and increasing API usage linked to AI adoption. Key risks include interest rate sensitivity in the ratings segment and competitive pressures. With 85.7% of analysts rating it a Buy and a consensus price target of $532.38, the stock offers significant upside potential, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
